Invention Grant
- Patent Title: Thienopyrimidinone NMDA receptor modulators and uses thereof
-
Application No.: US17186137Application Date: 2021-02-26
-
Publication No.: US11541057B2Publication Date: 2023-01-03
- Inventor: David R. Anderson , Robert A. Volkmann , Frank S. Menniti , Christopher Fanger
- Applicant: Cadent Therapeutics, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Cadent Therapeutics, Inc.
- Current Assignee: Cadent Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Michael J. DeGrazia
- Main IPC: A61K31/519
- IPC: A61K31/519 ; C07D495/04 ; A61P25/28 ; A61P25/18 ; A61P25/24

Abstract:
Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
Public/Granted literature
- US20220016117A1 THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF Public/Granted day:2022-01-20
Information query
IPC分类: